While a number of oral SERD (selective estrogen receptor degrader) breast cancer drugs are moving closer to the market, Menarini Groupand partner Radius Health, Inc. have moved ahead of the pack with promising late-stage data for elacestrant.
Menarini And Radius Skip Into SERD Lead With Elacestrant Success
Breast Cancer Therapy Improves PFS In Phase III EMERALD Trial
Elacestrant has become the first oral SERD to generate positive topline results in a pivotal study as a monotherapy versus standard of care for ER+/HER2- advanced or metastatic breast cancer.
More from Archive
• By
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
• By
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
• By
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
More from Scrip
• By
AstraZeneca and Daiichi’s DESTINY-Breast09 trial testing Enhertu with pertuzumab versus standard of care showed a statistically significant and meaningful PFS improvement.
• By
In the final part of this interview with Scrip, Menarini’s Asia-Pacific CEO talks about the Italian group’s digital capabilities, including the impact made during a shortage issue in Australia, and leveraging RWE to inform healthcare practices across the region. The company is also revving up its business development and alliance engine, with around 14 candidates under evaluation at different stages at the regional level.
• By
In this week's episode: Trump’s drug pricing executive order; J&J says taxes, not tariffs, influence US manufacturing; Pfizer discontinuation sparks M&A speculation; US tariffs and manufacturing concentration; and tariffs’ pressures on pharma’s complex supply chain.